Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ...

Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The companion product – Susvimo – is an implantable treatment based on ranibizumab that can extend the time between treatments to six months or more and was approved by the FDA last October.

In other recent news, Genentech, a part of Roche Group, announced the FDA's approval of Susvimo for the treatment of diabetic macular edema (DME). The approval follows positive results from the ...

The FDA has approved Susvimo, which delivers medicine continuously via a surgical implant that can be refilled every six months vs. getting monthly injections. For those with diabetic macular edema ...